WEST LAFAYETTE, Ind. — November 17, 2025 — Leads & Copy — Inotiv, Inc. (NASDAQ: NOTV) has released preliminary financial results for the fourth quarter and full year 2025, ending September 30, 2025.
The company anticipates fourth-quarter revenue between $137.5 million and $138.5 million. The book-to-bill ratio for the DSA services business is expected to be approximately 1.08x. The anticipated DSA backlog at September 30, 2025, is approximately $138.0 million, compared to $129.9 million at September 30, 2024, and $134.3 million at June 30, 2025.
For the full year 2025, Inotiv anticipates revenue between $512.5 million and $513.5 million. The book-to-bill ratio is expected to be approximately 1.05x for the DSA services business.
Robert Leasure Jr., President and Chief Executive Officer, noted the company continued to execute its financial goals outlined in May, with strong contract awards in Discovery and Safety Assessment (DSA) services, showing sequential growth in the fourth quarter and a 60% increase over the same period last year.
Inotiv has updated the time for Mr. Leasure’s presentation at the Jefferies Global Healthcare Conference in London, UK, to November 18, 2025, at 11:00 AM GMT/6:00 AM ET. The presentation will be available via live webcast in the Investors section of the company’s website, with an online replay for those unable to attend live.
Inotiv, Inc. is a contract research organization that provides nonclinical and analytical drug discovery and development services, research models, and related products. The company focuses on bringing new drugs and medical devices through the discovery and preclinical phases, increasing efficiency, improving data, and reducing market costs.
Beth A. Taylor, Chief Financial Officer, (765) 497-8381, beth.taylor@inotiv.com
Steve Halper, LifeSci Advisors, (646) 876-6455, shalper@lifesciadvisors.com
Source: Inotiv, Inc.
